Teva asthma, allergy drug approved by FDA

By JPOST.COM STAFF
August 5, 2012 16:13

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Teva Pharmaceuticals has received FDA approval to market generic asthma treatment, Globes reported on Sunday.

Teva Pharmaceutical Industries Ltd.is one of ten companies to obtain US Food and Drug Administration (FDA) approval for a version of Merck's asthma and allergies drug Singulair in adults and children. Brand Singulair, made by Merck & Co., has $5 billion in annual US sales.

Teva obtained approval for both tablet and oral granule forms of Singulair. Sandoz will reportedly launch cheaper generic versions of the drug, which will jointly win 66% of the market.

Montelukast, the active ingredient in the drug, is in a class of medications called leukotriene receptor antagonists. It works by blocking the action of leukotrienes, substances in the body that cause the symptoms of asthma and hay fever (allergic rhinitis).

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Breaking news
September 18, 2018
Jerusalem Post closed for Yom Kippur

By JERUSALEM POST STAFF